| |
Gain expert advice on navigating the stakeholder ecosystem—from payers and policymakers to patients and community oncologists. Download the eBook now to drive commercial success and outcomes in cancer care.
|
|
Today's Big NewsJul 19, 2023 |
| By James Waldron Pfizer has licensed a preclinical cardiovascular program from Riparian Pharmaceuticals as part of an agreement that will also see the Big Pharma support further discovery efforts by the biotech. |
|
|
|
By Zoey Becker The GSK-funded report looked at adult vaccination data and found a major slump in vaccine adoption over the last few years, save for COVID vaccines. |
By Andrea Park Medtronic has found that some of its cardiac implants may deliver either low-energy shocks or none at all even when they’ve been programmed to deliver high-voltage therapy. |
By Kevin Dunleavy Amarin is restructuring under new leadership following a takeover of its board by activist investor Sarissa Capital three months ago. The company will lay off its entire sales force in the United States and reduce its non-sales staff by 30%. Amarin also has hired a new CEO, Patrick Holt. |
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more.
|
|
By Max Bayer FibroGen's previously announced cost-cutting plans are taking shape, with the biotech announcing layoffs affecting 32% of its team. Arch-backed ImmuneID is also laying off staff to help push a lead asset into the clinic. |
By Andrea Park Boston Scientific will permanently close a facility in the San Francisco Bay Area, resulting in the layoffs of dozens of workers there. |
By Angus Liu After Novo Nordisk's Wegovy became hard to come by, people turned to the company first-generation weight loss drug, Saxenda, for treatment. Now, the company is struggling to handle demand for that product. |
By Conor Hale The infectious disease diagnostic company MeMed is taking a big step toward a larger market, courtesy of an FDA green light for its test that distinguishes between viral and bacterial cases. |
By Angus Liu,Kevin Dunleavy,Eric Sagonowsky In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
| WhitepaperLeading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| WhitepaperLearn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
